Transplant News and Research

RSS

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

Patient on artificial heart receives heart and kidney transplant

Charles Okeke, the Phoenix husband and father of three, made headlines in May 2010 when he became the first patient in the U.S. to be discharged from a hospital with an artificial heart. With the latest technology, the "Freedom Driver," the man without a heart was able to resume his family life and to be free of the confines of a hospital room.

16 Feb 2011

Sanofi-aventis enters definitive agreement to acquire Genzyme

Sanofi-aventis and Genzyme Corporation announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion.

16 Feb 2011

Gen-Probe board authorizes $150 million stock repurchase

Gen-Probe Incorporated announced today that its board of directors has authorized the repurchase of up to $150 million of the Company's common stock over the next year.

16 Feb 2011

Orthofix 2010 net sales increase 3% to $564.4 million

Orthofix International N.V. today announced its results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

AML patient raises awareness in community about national stem cell registry

By the age of 28, Dana Severson was already an Iraq war veteran, an accomplished clinical engineer, a wife and mother. Days following her daughter Genevieve's first birthday, Severson was faced with a reality that would turn her life upside down. After several weeks of experiencing severe headaches and extreme exhaustion, the young mother was diagnosed with acute myeloid leukemia.

16 Feb 2011

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor Pharmaceutical Corp., today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

15 Feb 2011

RPCs transplant appears to improve kidney structure and function in rat models

Transplanting autologous renal progenitor cells, into rat models with kidney damage from pyelonephritis - a type of urinary infection that has reached the kidney - has been found to improve kidney structure and function.

14 Feb 2011

Story of the heart: Literally as well as metaphorically

Stephen Amidon, a novelist and co-author of The Sublime Engine: A Biography of the Human Heart, writes about the story of the human heart through the world of science, history, culture and our bodies with his brother Thomas who is a practicing cardiologist in Montana and a former medical director of The Hope Heart Institute. Thomas said, “Ironically, I did an angiogram on a patient last week who had very calcified and hardened arteries that were almost precisely in the shape of the Valentine heart… But I don't think the early depicters of that heart shape had access to the same view of the heart that I have.”

14 Feb 2011

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

14 Feb 2011

U.S. FDA clears QMS Everolimus Immunoassay to prevent rejection in kidney transplants

The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients. The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus, a drug that helps prevent rejection in kidney transplants.

14 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.

10 Feb 2011

Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec

Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

Patients with sensorineural hearing loss can benefit from mucosa-derived stem cell transplant

Stem Cell scientists in Australia have found that patients suffering from hearing problems which began during infancy and childhood could benefit from a transplant of stem cells from their nose. The research, published today in STEM CELLS, reveals that mucosa-derived stem cells can help preserve hearing function during the early-onset of sensorineural hearing loss.

10 Feb 2011

Enrollment suspended in WorldHeart's Levacor Ventricular Assist Device Bridge-To-Transplant Study

World Heart Corporation, a developer of mechanical circulatory systems, announced today that it has paused enrollment in its Levacor Ventricular Assist Device (VAD) Bridge-To-Transplant (BTT) Study pending U.S. Food and Drug Administration (FDA) review and approval of the previously announced device refinements.

10 Feb 2011

IDF commends Illinois advisory committee for unanimous vote to recommend SCID Newborn Screening

The Illinois Genetic and Metabolic Diseases Advisory Committee voted unanimously to recommend that the Department of Health screen all newborns for Severe Combined Immune Deficiency (SCID) - commonly known as bubble boy disease.

9 Feb 2011

Rational use of heath care dollars for tonsillectomy

Without fanfare, hundreds of thousands of children surrender their tonsils to a surgeon's scalpel each year, usually to alleviate recurring infections and obstructive sleep problems. Most of the time, the snipped tonsils are sent to a pathologist, who looks for evidence of more serious medical problems, like unsuspected cancer.

9 Feb 2011

Transplant News and Research

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Patient on artificial heart receives heart and kidney transplant

Sanofi-aventis enters definitive agreement to acquire Genzyme

Gen-Probe board authorizes $150 million stock repurchase

Orthofix 2010 net sales increase 3% to $564.4 million

AML patient raises awareness in community about national stem cell registry

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

RPCs transplant appears to improve kidney structure and function in rat models

Story of the heart: Literally as well as metaphorically

Chimerix announces completion of $45 million Series F financing

U.S. FDA clears QMS Everolimus Immunoassay to prevent rejection in kidney transplants

Vical 2010 net loss increases to $30.4 million

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Patients with sensorineural hearing loss can benefit from mucosa-derived stem cell transplant

Enrollment suspended in WorldHeart's Levacor Ventricular Assist Device Bridge-To-Transplant Study

IDF commends Illinois advisory committee for unanimous vote to recommend SCID Newborn Screening

Rational use of heath care dollars for tonsillectomy

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News